Genovis

Executive Summary

Genovis is a Swedish nanotechnology company specializing in SmartEnzymes™ for biologics and genomics applications. Founded in 2001 and headquartered in Lund, Sweden, the company develops advanced enzyme tools to improve the production and efficacy of biologics, including gene therapies and monoclonal antibodies. Its proprietary enzyme platforms aim to reduce neutralizing antibodies and enable large-scale manufacturing, addressing critical bottlenecks in bioprocessing. Genovis serves the biopharmaceutical industry through custom services and off-the-shelf products, positioning itself as a key enabler in the next generation of genomic and biologic therapies. As a private company with a long track record, Genovis is poised to capitalize on growing demand for high-performance enzymes in gene therapy and biomanufacturing, though public financial details are limited.

Upcoming Catalysts (preview)

• Q3 2026New product launch for gene therapy manufacturing65% success
• H2 2026Strategic partnership with a major biopharma company50% success
• Q4 2026Completion of a new funding round to scale production70% success